Compare Bill.com Holdings Inc (BILL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs TG Therapeutics Inc — how do they compare? Bill.com Holdings Inc trades at $49.45 (market cap $4.93B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BILL | TGTX | |
|---|---|---|
Market Cap | $4.93B | $7.64B |
Sector | Technology | Health |
52-Week High | $56.32 | $59.06 |
52-Week Low | $31.96 | $26.94 |
Enterprise Value | $4.64B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.63, down 1.28% on the day, with a bullish technical signal from moving averages and positive earnings beats in recent quarters. Revenue growth is strong, reaching $1.46B in 2025, but profitability remains thin with a net income margin of just 0.01%. The company is focusing on AI-driven automation and operational efficiency, including a recent 30% workforce reduction and new executive appointments to spur growth.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56%) and a price target implying modest upside. Key risks include intense fintech competition and the challenge of translating high revenue into sustained profitability. Cash flow trends show improvement, but investors should monitor execution on margin expansion and competitive positioning.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
